Compounds > lapatinib
Page last updated: 2024-09-05

lapatinib and gsk690693

lapatinib has been researched along with gsk690693 in 5 studies

Compound Research Comparison

Studies
(lapatinib)		Trials
(lapatinib)		Recent Studies (post-2010)
(lapatinib)		Studies
(gsk690693)		Trials
(gsk690693)		Recent Studies (post-2010) (gsk690693)
1,9193051,44252041

Protein Interaction Comparison

ProteinTaxonomylapatinib (IC50)gsk690693 (IC50)
Death-associated protein kinase 3Homo sapiens (human)0.081
Ribosomal protein S6 kinase alpha-5Homo sapiens (human)1.991
Serine/threonine-protein kinase PAK 4Homo sapiens (human)0.01
Protein kinase C beta typeHomo sapiens (human)0.019
Muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)0.009
Protein kinase C eta typeHomo sapiens (human)0.002
RAC-alpha serine/threonine-protein kinaseHomo sapiens (human)0.0192
RAC-beta serine/threonine-protein kinaseHomo sapiens (human)0.01
RAC-alpha serine/threonine-protein kinaseRattus norvegicus (Norway rat)6.97
Glycogen synthase kinase-3 betaHomo sapiens (human)0.138
cAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)0.005
Protein kinase C epsilon typeHomo sapiens (human)0.021
Protein kinase C theta typeHomo sapiens (human)0.002
Protein kinase C delta typeHomo sapiens (human)0.014
5'-AMP-activated protein kinase catalytic subunit alpha-2Rattus norvegicus (Norway rat)0.05
Rho-associated protein kinase 1Homo sapiens (human)0.2285
cGMP-dependent protein kinase 1 Homo sapiens (human)0.033
Ribosomal protein S6 kinase alpha-1Homo sapiens (human)0.321
Rho-associated protein kinase 1 Rattus norvegicus (Norway rat)0.008
Serine/threonine-protein kinase PAK 6Homo sapiens (human)0.006
Serine/threonine-protein kinase PAK 5Homo sapiens (human)0.052
RAC-gamma serine/threonine-protein kinaseHomo sapiens (human)0.0084

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP1
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP1
Boddapati, S; Gray, JW; Iacovides, DC; Johnson, AB; Korkola, J; Wang, N1
Bayani, N; Billig, J; Collisson, EA; Cooper, B; Esch, A; Feiler, H; Gray, JW; Griffith, OL; Heiser, M; Hung, JL; Itani, S; Jakkula, L; Korkola, JE; Kuo, WL; Lu, Y; Mills, GB; Mukherjee, S; Oates, C; Spellman, PT; Thompson, W; Tomlin, C; Wang, NJ; Ziyad, S1

Other Studies

5 other study(ies) available for lapatinib and gsk690693

ArticleYear
Comprehensive analysis of kinase inhibitor selectivity.
    Nature biotechnology, 2011, Oct-30, Volume: 29, Issue:11

    Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity

2011
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
The target landscape of clinical kinase drugs.
    Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017
Identification and quantification of AKT isoforms and phosphoforms in breast cancer using a novel nanofluidic immunoassay.
    Molecular & cellular proteomics : MCP, 2013, Volume: 12, Issue:11

    Topics: Breast Neoplasms; Cell Line, Tumor; Electrophoresis, Capillary; Female; Humans; Immunoassay; Isoenzymes; Lapatinib; Metabolic Networks and Pathways; Microfluidic Analytical Techniques; Nanotechnology; Oxadiazoles; Phosphorylation; Protein Kinase Inhibitors; Proteomics; Proto-Oncogene Proteins c-akt; Quinazolines

2013
Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer.
    PloS one, 2015, Volume: 10, Issue:7

    Topics: Antineoplastic Agents; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Diamines; Drug Resistance, Neoplasm; Epithelial Cells; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mammary Glands, Human; Mutation; Oxadiazoles; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazoles; Quinazolines; Receptor, ErbB-2; Ribosomal Protein S6; Signal Transduction

2015